Review



qmsp-based mgmt promoter methylation testing  (MDxHealth)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MDxHealth qmsp-based mgmt promoter methylation testing
    Qmsp Based Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+testing/mgmt+promoter+methylation+testing/pm33113214-56-1-16
    Average 90 stars, based on 1 article reviews
    qmsp-based mgmt promoter methylation testing - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Methylation:

    Article Title: Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis
    Article Snippet: .. MDxHealth did the MGMT promoter methylation testing free of charge. .. In France, Merck provided temozolomide free of charge.

    Article Title: A Safety Run-in and Randomized Phase II Study of Cilengitide Combined with Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)
    Article Snippet: .. MGMT Promoter Methylation Testing Patient samples were tested for MGMT promoter methylation status using previously described procedures ( 11 ) by MDxHealth (Liege, Belgium). ..

    Article Title: PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Article Snippet: Statistical analysis was performed in JMP, version 10.0 (SAS Institute Inc., Cary, North Carolina, USA) and in SPSS, version 22. .. MDxHealth performed the MGMT promoter methylation testing for samples included in the Nordic trial of elderly patients with glioblastoma free of charge. ..

    Article Title: Assessment of DNA Repair Mechanisms to Determine the Susceptibility of Non-small Cell Lung Cancer to Alkylating Agents
    Article Snippet: .. We would like to thank Kathleen Carrier, histologist at the Maine Medical Center Research Institute, for her expert sectioning of all the tissue blocks and Greg Jones, Program manager at MDxHealth, for mediating the MGMT promoter methylation testing. .. This work was funded by an unrestricted research grant from Schering-Plough XX-3807 (IFE & CB).

    Article Title: Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
    Article Snippet: Introduction Glioblastoma is the most frequent primary brain tumour and is mainly seen in people older than 60 years.. Median survival is less than 1 year.. Chemoradiotherapy with temozolomide became the standard of care in 2004, but its introduction was based on a pivotal study in which patients were aged 70 years or younger; increasing age was found to be a negative prognostic factor.



    Similar Products

    mgmt promoter methylation test  (Kiyatec Inc)
    90
    Kiyatec Inc mgmt promoter methylation test
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Test, supplied by Kiyatec Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+testing/mgmt+methylation+test/pmc11358395-240-14-11
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation test - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mgmt promoter methylation status testing  (Covance)
    90
    Covance mgmt promoter methylation status testing
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Status Testing, supplied by Covance, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+testing/mgmt+promoter+methylation+status+testing/pm35419607-51-6-14
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation status testing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    qmsp-based mgmt promoter methylation testing  (MDxHealth)
    90
    MDxHealth qmsp-based mgmt promoter methylation testing
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Qmsp Based Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+testing/mgmt+promoter+methylation+testing/pm33113214-56-1-16
    Average 90 stars, based on 1 article reviews
    qmsp-based mgmt promoter methylation testing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mgmt promoter methylation testing free of charge  (MDxHealth)
    90
    MDxHealth mgmt promoter methylation testing free of charge
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Testing Free Of Charge, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+testing/mgmt+promoter+methylation+testing/pmc07086476-420-51-48
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation testing free of charge - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    mgmt promoter methylation testing  (MDxHealth)
    90
    MDxHealth mgmt promoter methylation testing
    3D Predict Glioma identified those patients with an unmethylated <t>MGMT</t> promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter <t>methylation</t> in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.
    Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mgmt+promoter+methylation+testing/mgmt+promoter+methylation+testing/pmc07086476-4830-3-0
    Average 90 stars, based on 1 article reviews
    mgmt promoter methylation testing - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    3D Predict Glioma identified those patients with an unmethylated MGMT promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: 3D Predict Glioma identified those patients with an unmethylated MGMT promoter that still did well with temozolomide treatment. ( a ) Individual patient information and drug response. ( b,c ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the HGG ( b ) and GBM ( c ) populations. ( d ) Table summarizing the PFS and OS and corresponding statistics for GBM patients with an unmethylated MGMT promoter (GBM, MGMT U ). ( e,f ) Kaplan–Meier survival curves for GBM, MGMT U patients for PFS ( e ) and OS ( f ) separated by test-predicted responders (green) and test-predicted non-responders (red). The dashed black line is the patient population unseparated by test prediction.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Methylation

    3D Predict Glioma stratified patient response regardless of the MGMT promoter methylation test used. ( a ) bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( b ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( c,e ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( c ) and pyrosequencing ( e ) tested populations. ( d,f ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( d ) and pyrosequencing ( f ) tested populations.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: 3D Predict Glioma stratified patient response regardless of the MGMT promoter methylation test used. ( a ) bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( b ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( c,e ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( c ) and pyrosequencing ( e ) tested populations. ( d,f ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( d ) and pyrosequencing ( f ) tested populations.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Methylation

    Standardization of MGMT promoter methylation testing affects MGMT promoter methylation categorization. ( a,b ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the GBM population as a conglomerate of multiple test types ( a ) and tested with Kiyatec’s MGMT methylation test ( b ). ( c ) Bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( d ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( e,g ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( e ) and pyrosequencing ( g ) tested populations. ( f,h ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( f ) and pyrosequencing ( h ) tested populations.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: Standardization of MGMT promoter methylation testing affects MGMT promoter methylation categorization. ( a,b ) Kaplan–Meier survival curves stratified by MGMT promoter methylation in the GBM population as a conglomerate of multiple test types ( a ) and tested with Kiyatec’s MGMT methylation test ( b ). ( c ) Bar graph indicating the different tests used to clinically determine MGMT promoter methylation, including the number of methylated (light purple), unmethylated (dark purple) and inconclusive (gray) patients identified with each test type. ( d ) Table summarizing the OS for each test and categorization of patients along with the associated statistics. ( e,g ) Kaplan–Meier survival curves of the populations stratified by methylation state for the msPCR ( e ) and pyrosequencing ( g ) tested populations. ( f,h ) Kaplan–Meier survival curves of the populations stratified by 3D Predict Glioma test prediction for the msPCR ( f ) and pyrosequencing ( h ) tested populations.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Methylation

    Demographics of patients at clinical correlation, Irrespective of study predicted treatment response.

    Journal: Scientific Reports

    Article Title: Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma

    doi: 10.1038/s41598-024-68801-0

    Figure Lengend Snippet: Demographics of patients at clinical correlation, Irrespective of study predicted treatment response.

    Article Snippet: When enough cells were available, MGMT promoter methylation was assayed using Kiyatec’s in-house, validated MGMT promoter methylation test to compare with and standardize the MGMT promoter methylation categorization coming from individual clinical sites.

    Techniques: Histopathology, Mutagenesis, Methylation